1-[2-(N-hydroxy-C-methylcarbonimidoyl)-1H-imidazol-5-yl]butane-1,2,3,4-tetrol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2-(N-hydroxy-C-methylcarbonimidoyl)-1H-imidazol-5-yl]butane-1,2,3,4-tetrol
• 化学式: C₉H₁₅N₃O₅
• 分子量: 245.23
• InChiKey: AMXVYJYMZLDINS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  142
• 氢给体数：
  6
• 氢受体数：
  7

文献信息

• ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY
  申请人：AC BioScience

  公开号：EP3668506A1

  公开（公告）日：2020-06-24
• [EN] ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY<br/>[FR] AMÉLIORATION DE L'EFFICACITÉ DE TRAITEMENT DU CANCER PAR L'INTERMÉDIAIRE DE LA VOIE SPHINGOSINE-1-PHOSPHATE
  申请人：AC BIOSCIENCE

  公开号：WO2019034768A1

  公开（公告）日：2019-02-21

  The present invention relates to neoadjuvant prior to chemotherapy. The present invention relates to sphingosine-1-phosphate pathway activator for use in the treatment of cancer as neoadjuvant prior to chemotherapy selected from sphingosine-1-phosphate lyase inhibitors. The sphingosine-1-phosphate pathway activator enhances the chemotherapy efficiency through the normalization of intratumoral vascular network, promoting the effects of the sequential administration of an anticancer agent or a sequential radiotherapy.